ArticlePostepy dermatologii i alergologii2025
Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Physician Awareness of Hereditary Angioedema: A Cross-Sectional Survey with Emphasis on Medication-Related Triggers.Journal of clinical medicine · 2026Article
- Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema.Journal of patient-reported outcomes · 2026Article
- A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.Frontiers in immunology · 2026Article
- A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hereditary angioedema (HAE) significantly affects patients' quality of life due to its life-threatening potential and the unpredictability of attacks. Aim: To determine strategic goals to reduce the frequency of attacks and improve the quality of life by evaluating the attack triggers, attack management strategies, and medication use attitudes of HAE patients treated in our clinic. Material and methods: Patients who were followed up in our clinic with a diagnosis of HAE in 2022-2023 were included in the study. Patient data were obtained by retrospective scanning of file records. Results: The analysis included 23 HAE patients with an average age of 34.7 years, predominantly female (60.9%). In the patients' family history, there was a high prevalence of HAE (95.7%) and HAE-related death (73.9%). The median duration of HAE diagnostic delay was 9 years (0-50). A significant positive correlation was found between patient age and the duration of diagnostic delay ( Conclusions: The high frequency of attacks in our patients was related to the lack of use of LTP agents and personal life stress. Despite severe attacks and a family history of HAE-related deaths, pharmacophobia to LTP was common, with pharmacophobia resulting from side effects of second-line LTP agents. Our findings highlight the need for our patients to have access to psychosocial support programs and first-line LTP agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.